Cantargia reports positive preclinical effects in atherosclerosis demonstrating potential of CAN10 in cardiovascular disease
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical results, demonstrating efficacy of the IL1RAP-binding antibody CAN10 in a preclinical disease model for atherosclerosis. Treatment with a CAN10 surrogate antibody reduced plaque burden and plaque inflammation in this model, supporting the potential of CAN10 as a potent therapeutic in cardiovascular disease. These findings will be presented at the European Atherosclerosis Society (EAS) Congress in Milan on 22-25 May.“These new results highlight the potential of CAN10 in various inflammatory diseases and